Jörg H W Distler Selected Research

Fos-Related Antigen-2

11/2017	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
8/2012	Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis.
1/2010	The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jörg H W Distler Research Topics

Disease

94	Fibrosis (Cirrhosis) 01/2022 - 01/2007
77	Systemic Scleroderma (Systemic Sclerosis) 01/2022 - 02/2004
17	Inflammation (Inflammations) 01/2022 - 12/2006
11	Bronchiolitis Obliterans Syndrome 01/2022 - 01/2010
9	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 09/2017
9	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022 - 08/2008
8	Hypoxia (Hypoxemia) 01/2022 - 07/2004
7	Vascular Diseases (Vascular Disease) 01/2020 - 01/2009
7	Rheumatoid Arthritis 01/2019 - 05/2004
6	Idiopathic Pulmonary Fibrosis 01/2022 - 07/2013
6	Neoplasms (Cancer) 01/2021 - 02/2007
5	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 02/2007
5	Disease Progression 11/2020 - 07/2013
5	Arthritis (Polyarthritis) 01/2019 - 12/2006
4	Pulmonary Arterial Hypertension 11/2017 - 07/2011
3	Osteoarthritis 03/2015 - 05/2004
2	Sarcoidosis (Schaumann Disease) 12/2022 - 01/2021
2	COVID-19 12/2022 - 01/2021
2	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2021 - 01/2020
2	Arthralgia (Joint Pain) 01/2021 - 01/2021
2	Myositis (Idiopathic Inflammatory Myopathies) 01/2020 - 07/2011
2	Neointima 07/2018 - 01/2018
2	Connective Tissue Diseases (Connective Tissue Disease) 01/2018 - 08/2008
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2018 - 01/2013
2	Necrosis 10/2012 - 01/2007
2	Vasculitis (Vasculitides) 03/2012 - 11/2010
2	Eosinophilia 03/2012 - 11/2010
2	Churg-Strauss Syndrome (Allergic Angiitis) 03/2012 - 11/2010
2	Mixed Connective Tissue Disease (MCTD) 07/2011 - 08/2008
1	Diarrhea 01/2022
1	Lung Diseases (Lung Disease) 01/2022
1	Bronchiolitis Obliterans 01/2022

Drug/Important Bio-Agent (IBA)

57	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 01/2007
24	CollagenIBA 06/2021 - 12/2007
16	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 05/2012
14	indium-bleomycinIBA 01/2018 - 08/2007
13	Hydroxyproline (4 Hydroxyproline)IBA 07/2021 - 11/2010
11	nintedanibIBA 01/2022 - 05/2016
11	CytokinesIBA 01/2022 - 12/2006
10	Imatinib Mesylate (Gleevec)FDA Link 01/2019 - 01/2007
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 02/2004
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2007
7	EnzymesIBA 01/2021 - 11/2010
6	Transforming Growth Factor beta (TGF-beta)IBA 06/2021 - 01/2009
5	Small Interfering RNA (siRNA)IBA 01/2022 - 05/2012
5	Transcription Factors (Transcription Factor)IBA 01/2022 - 03/2011
5	Extracellular Matrix ProteinsIBA 01/2021 - 12/2007
5	Phosphotransferases (Kinase)IBA 01/2019 - 07/2008
5	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 11/2017 - 07/2008
5	Tyrosine Kinase InhibitorsIBA 09/2017 - 08/2008
4	AntibodiesIBA 01/2021 - 03/2012
4	Tyrosine (L-Tyrosine)FDA Link 01/2019 - 07/2013
4	Soluble Guanylyl CyclaseIBA 01/2018 - 06/2012
4	Interleukin-6 (Interleukin 6)IBA 06/2017 - 12/2012
3	GlucocorticoidsIBA 12/2022 - 11/2020
3	LigandsIBA 01/2022 - 03/2014
3	Carbon MonoxideIBA 01/2022 - 09/2017
3	Platelet-Derived Growth FactorIBA 01/2022 - 07/2008
3	AutoantibodiesIBA 01/2022 - 04/2009
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2020
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2017
3	Type I DNA Topoisomerases (Topoisomerase I)IBA 01/2021 - 06/2017
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 03/2012
3	Fos-Related Antigen-2IBA 11/2017 - 01/2010
3	DNA (Deoxyribonucleic Acid)IBA 06/2014 - 12/2009
3	CateninsIBA 03/2014 - 05/2012
3	interleukin-21 (interleukin 21)IBA 07/2013 - 05/2004
3	Histones (Histone)IBA 04/2013 - 04/2007
3	nilotinib FDA Link 11/2012 - 07/2008
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 10/2015
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 06/2021 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2021 - 03/2012
2	Annexin A5IBA 12/2019 - 12/2006
2	Rituximab (Mabthera)FDA Link 01/2019 - 06/2015
2	pomalidomideIBA 01/2018 - 11/2012
2	ImmunosorbentsIBA 01/2018 - 11/2010
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2017 - 01/2009
2	Pharmaceutical PreparationsIBA 08/2015 - 01/2007
2	MicroRNAs (MicroRNA)IBA 03/2015 - 06/2010
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 10/2014 - 07/2011
2	Monoclonal AntibodiesIBA 07/2013 - 06/2013
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 07/2013 - 01/2009
2	CannabinoidsIBA 12/2012 - 09/2012
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 05/2012 - 07/2011
2	Immunoglobulin E (IgE)IBA 03/2012 - 11/2010
2	Fibronectins (Fibronectin)IBA 05/2009 - 12/2007
2	theasinensin AIBA 05/2009 - 08/2007
2	trichostatin A (A 300)IBA 05/2009 - 08/2007
2	Histone Deacetylases (Histone Deacetylase)IBA 05/2009 - 04/2007
2	Oxygen (Dioxygen)IBA 12/2007 - 07/2004
2	Interleukin-21 ReceptorsIBA 03/2005 - 05/2004
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	LDL Receptors (LDL Receptor)IBA 01/2022
1	P-SelectinIBA 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	mitochondrial transcription factor AIBA 01/2022
1	oxidized low density lipoproteinIBA 01/2022

Therapy/Procedure

12	Therapeutics 01/2021 - 01/2010
2	Transplantation 01/2018 - 04/2009
1	Cell Transplantation 01/2022